New scan technique could sharpen cancer imaging

NCT ID NCT07646873

Not yet recruiting Knowledge-focused Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests a new imaging method called PET-enabled dual-energy CT to measure bone and soft tissue in the bone marrow. It will include 45 adults: some with multiple myeloma scheduled for CAR T-cell therapy and some healthy volunteers. The goal is to see if this new method matches standard X-ray dual-energy CT and whether it can help track treatment response. The study is not expected to directly help participants but may improve future cancer imaging.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-FDG (a radioactive tracer used in PET scans)
What this could lead to: If successful, this could improve how doctors use PET/CT scans to evaluate bone marrow health and treatment response in multiple myeloma.
What could go wrong: This is a very early pilot study with only 45 participants. It is designed to test the imaging method, not to provide direct benefit, so results may not change patient care soon.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA (MM)

Contacts and locations

Locations

UC Davis EXPLORER Molecular Imaging Center

Sacramento, California, 95816, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.